aTyr Securities Suits Intensify as New Filing Expands Class Period Ahead of Dec. 8 Deadline
The complaints center on claims that executives overstated efzofitimod's ability to eliminate steroid use in the EFZO‑FIT trial.
Overview
- Hagens Berman announced a new complaint, King v. aTyr Pharma, that widens the alleged class period to Nov. 7, 2024 through Sept. 12, 2025 in the Southern District of California.
- Other firms, including Rosen Law and Bronstein, Gewirtz & Grossman, are soliciting shareholders using a narrower class period starting Jan. 16, 2025.
- Filings allege materially misleading statements about efzofitimod’s efficacy and the EFZO‑FIT forced‑taper design, with a focus on claims about complete steroid withdrawal.
- aTyr disclosed on Sept. 15, 2025 that EFZO‑FIT failed its primary endpoint on steroid dose reduction at week 48, after which the stock fell about 83% in one day.
- Litigation remains at an early stage with no class certified, and the company has said it plans to engage the FDA on next steps.